GSK3 inhibitors: development and therapeutic potential
Top Cited Papers
- 1 June 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 3 (6) , 479-487
- https://doi.org/10.1038/nrd1415
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation eventBiochemical Journal, 2004
- Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3The Journal of Pharmacology and Experimental Therapeutics, 2003
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- Intestinal polyposis in mice with a dominant stable mutation of the beta -catenin geneThe EMBO Journal, 1999
- Tau is a candidate gene for chromosome 17 frontotemporal dementiaAnnals of Neurology, 1998
- In Vitro Phosphorylation of the Cytoplasmic Domain of the Amyloid Precursor Protein by Glycogen Synthase Kinase‐3βJournal of Neurochemistry, 1996
- Characterization of mAb AP422, a novel phosphorylation‐dependent monoclonal antibody against tau proteinFEBS Letters, 1996
- Glycogen synthase kinase-3β phosphorylates tau protein at multiple sites in intact cellsNeuroscience Letters, 1995
- Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinaseNeuroscience Letters, 1992
- Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's diseaseNature, 1991